2022 | The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70 | Boutry C.; Hastie A.; Diez-Domingo J.; Tinoco J.C.; CHONG-JEN YU ; Andrews C.; Beytout J.; Caso C.; Cheng H.-S.; Cheong H.J.; Choo E.J.; Curiac D.; Di Paolo E.; Dionne M.; Eckermann T.; Esen M.; Ferguson M.; Ghesquiere W.; Hwang S.-J.; Avelino-Silva T.J.; Kosina P.; Liu C.-S.; Markkula J.; Moeckesch B.; Murta de Oliveira C.; Park D.W.; Pauksens K.; Pirrotta P.; Plassmann G.; Pretswell C.; Rombo L.; Salaun B.; Sanmartin Berglund J.; Schenkenberger I.; Schwarz T.; Shi M.; Ukkonen B.; Zahaf T.; Zerbini C.; Schuind A.; Cunningham A.L.; Zoster-049 Study Group | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 40 | 29 | |